Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Laboratory analysis of symptomatic and asymptomatic pregnant patients with SARS-CoV-2 infection

Stephanie A. Fisher, MD, MPH; Jeffery A. Goldstein, MD, PhD; Leena B. Mithal, MD, MSCI; Alexandra L. Isaia, BS; Elisheva D. Shanes, MD; Sebastian Otero, BA; Emily S. Miller, MD, MPH

BACKGROUND: Inflammatory biomarkers have been used to portend disease severity in nonpregnant individuals with SARS-CoV-2 infection. However, currently, limited data are available, and with mixed results, to elucidate which inflammatory biomarkers may be most associated with clinical phenotype in pregnant patients.

OBJECTIVE: We aimed to compare laboratory findings among pregnant patients with SARS-CoV-2 infection by symptom status and disease severity.

STUDY DESIGN: We retrospectively evaluated pregnant patients with positive SARS-CoV-2 infection, confirmed through polymerase chain reaction testing, at an urban academic US hospital between March 2020 and October 2020, performed for reported symptoms or universal screening on admission. In our hospital, all patients with SARS-CoV-2 infection were recommended to have baseline laboratory testing, including leukocyte, neutrophil, and lymphocyte counts; aspartate aminotransferase and alanine aminotransferase; high-sensitivity C-reactive protein; procalcitonin; lactate dehydrogenase; D-dimer; and ferritin. We performed multivariable logistic regression to evaluate peak laboratory abnormalities significantly associated with symptomatic SARS-CoV-2 infection and disease severity with gestational age at diagnosis, maternal age, and obesity as covariates. The sensitivity and specificity of laboratory abnormalities were calculated to identify symptomatic vs asymptomatic infection and severe to critical disease vs mild to moderate disease.

RESULTS: We identified 175 pregnant patients with SARS-CoV-2 infection, of whom 100 (57%) were symptomatic; 17 (17%) of those who were symptomatic had a severe to critical disease. Laboratory data were available for 128 patients, of whom 67 (52%) were symptomatic. Compared with asymptomatic individuals, symptomatic individuals were more likely to exhibit elevated high-sensitivity C-reactive protein levels after adjusting for gestational age (adjusted odds ratio, 5.67; 95% confidence interval, 1.42−22.52; sensitivity, 81%; specificity, 43%). In symptomatic individuals, transaminits (adjusted odds ratio, 5.67; 95% confidence interval, 1.27−25.43), elevated procalcitonin levels (adjusted odds ratio, 16.60; 95% confidence interval, 2.61−105.46), and elevated lactate dehydrogenase levels (adjusted odds ratio, 17.55; 95% confidence interval, 2.51−122.78) were independently associated with severe to critical disease rather than mild to moderate disease after adjusting for maternal age and obesity. For differentiating disease severity, sensitivity rates for transaminits, procalcitonin elevation, and lactate dehydrogenase elevation were 47%, 87%, and 53%, respectively, whereas the specificity rates were 89%, 63%, and 90%, respectively.

CONCLUSION: Inflammatory biomarkers in pregnant patients with SARS-CoV-2 infection exhibited vast heterogeneity, poor discriminative ability, and thereby limited clinical utility. Larger registry studies should evaluate which inflammatory biomarkers may be most useful for risk stratification and prognostication of pregnant patients with SARS-CoV-2 infection, taking into account the physiology of pregnancy.

Key words: Inflammatory biomarkers in pregnancy, SARS-CoV-2 infection in pregnancy

Introduction

Pregnant women are more likely to experience severe sequelae after SARS-CoV-2 infection, presumably because of physiological changes in pregnancy that alter immune function.1−4 In the United States, from March 2020 to August 2020, approximately 1 in 4 reproductive-aged patients who were hospitalized for SARS-CoV-2 infection was pregnant, and as of October 29, 2020, SARS-CoV-2 has infected nearly 35,000 pregnant women, resulting in 50 maternal deaths.5,6 Amid a rapidly evolving pandemic, several small case series have determined that most pregnant women with SARS-CoV-2 infection will have a mild clinical phenotype, but a clinically significant minority of pregnant women with SARS-CoV-2 infection will develop a severe illness.3,7−10

In the nonpregnant population, several inflammatory biomarkers show promise in facilitating risk stratification and prognostication of patients with severe SARS-CoV-2 infection, including leukocyte, neutrophil, and lymphocyte counts; aspartate and alanine aminotransferase; C-reactive protein (CRP); procalcitonin (PCT); lactate dehydrogenase (LDH); D-dimer; and ferritin.11−15 However, several of these biomarkers, especially white blood cell count and differential, D-dimer, CRP, and ferritin are physiologically altered in pregnancy, challenging the clinical integration of these results. Although some studies have evaluated subsets of biomarkers to clinically distinguish pregnant women based on symptoms or severity of symptoms, the small sample sizes have precluded meaningful conclusions.16−21 As such, we do not have a clear laboratory-based approach to evaluate pregnant patients with SARS-CoV-2 infection.

As inflammatory biomarkers may provide insight into disease severity in individuals with SARS-CoV-2 infection, they have the potential to predict a
clinical trajectory and thereby impact clinical care in pregnant patients with SARS-CoV-2 infection. Given the limited data currently available to elucidate which inflammatory biomarkers may be most associated with clinical phenotype in pregnant patients, we aimed to compare laboratory findings among symptomatic and asymptomatic pregnant patients infected with SARS-CoV-2. We further examined the differences in biomarkers among symptomatic pregnant patients with SARS-CoV-2 infection according to disease severity.

Materials and Methods
In this retrospective cohort study conducted at Northwestern Memorial Hospital, an urban academic tertiary care center in Chicago, Illinois, we evaluated pregnant patients with positive SARS-CoV-2 infection, confirmed through polymerase chain reaction (PCR) testing, between March 2020 and October 2020. Pregnant patients were included if they had a positive SARS-CoV-2 test during the study period, were currently pregnant (determined by a positive pregnancy test or ultrasound), and presented to our hospital for care. Testing was performed as part of routine clinical care in the ambulatory and inpatient settings for reported symptoms consistent with SARS-CoV-2 infection, known exposure to individuals with SARS-CoV-2 infection, or as a universal screening protocol at the time of inpatient admission for labor and antepartum management. All individuals who underwent testing were systematically queried regarding symptoms and exposure to sick contacts using a standardized review of symptoms at the time of presentation for testing and were coded as symptomatic if any of the following symptoms was present: headache; anosmia; ageusia; fever; chills; fatigue; malaise; myalgias; chest pain or discomfort; cough; congestion; sore throat; shortness of breath, dyspnea, respiratory distress, or wheezing; or nausea, vomiting, diarrhea, or abdominal pain (unrelated to contractions or other labor symptoms).

Symptomatic individuals were admitted if they had unstable vital signs, required oxygen supplementation, reported significant shortness of breath or respiratory symptoms, or felt to be at risk of subsequent clinical deterioration. Apart from that, clinically stable pregnant women not warranting admission had outpatient telehealth follow-up for monitoring of symptoms. In our hospital, all patients who tested positive for SARS-CoV-2, irrespective of pregnancy, were recommended to have baseline laboratory test results with a complete blood cell count with differential to assess neutrophil and lymphocyte percentages and leukocyte counts; chemistry panel to evaluate aspartate aminotransferase (AST) and alanine aminotransferase (ALT); and additional testing for the following biomarkers that were selected a priori on the basis of their potential to stratify disease severity: high-sensitivity CRP (hsCRP), PCT, LDH, D-dimer, and ferritin. Laboratory test results were systematically queried for reported symptoms consistent with SARS-CoV-2 infection; alternatively, the clinical suspicion of worsening pulmonary disease or concern for superimposed bacterial pneumonia was used to guide the decision for radiographic evaluation.

Disease severity was classified with guidance from the National Institutes of Health’s COVID-19 Treatment Guidelines into asymptomatic infection (individuals who test positive for SARS-CoV-2, but with no current symptoms consistent with SARS-CoV-2), mild illness (individuals with any of the various signs and symptoms of SARS-CoV-2, but do not have shortness of breath, dyspnea, or abnormal chest imaging), moderate illness (individuals who show evidence of lower respiratory disease on clinical assessment or imaging and with oxygen saturation of ≥94% on room air), severe illness (individuals with oxygen saturation of <94% on room air, respiratory rate of >30 breaths per minute, a ratio of arterial partial pressure of oxygen to the fraction of inspired oxygen of <300 mm Hg, or lung infiltrates of >50%), and critical illness (individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction). However, as the threshold for...
oxygen supplementation in pregnancy is to maintain an oxygen saturation of ≥95% on room air, we classified any woman requiring oxygen supplementation as having a severe illness (ie, oxygen saturation of <95% on room air), with moderate illness thereby encompassing evidence of lower respiratory disease with an oxygen saturation of ≥95% on room air.

Pregnant patients were stratified by the presence of symptoms and severity of illness. Pregnant patients with mild to moderate disease were compared with those with severe to critical disease. If patients initially presented with mild to moderate disease, but subsequently demonstrated progression to a severe to critical disease, they were assigned to and analyzed among the severe to critical disease group. Maternal baseline sociodemographic and clinical characteristics were compared by both the presence and severity of symptoms in bivariable analyses. Obesity was defined as a body mass index of ≥30 kg/m². Independent samples t tests and Mann-Whitney U tests compared normally and abnormally distributed continuous variables, respectively. Chi-square test and the Fisher exact test were used to compare categorical variables. A P value of <.05 was considered statistically significant.

Median peak laboratory values, among all laboratory data available for the patient within 14 days of a positive SARS-CoV-2 test result, were compared according to symptom status and the severity of illness using independent samples t tests and Mann-Whitney U tests in bivariable analyses. As SARS-CoV-2 infection has been associated with leukopenia in nonpregnant patients, we compared the nadir of neutrophil percentage, lymphocyte percentage, and leukocyte count between the groups.23 The data included were cross-sectional; only the highest (or the lowest) biomarker level was analyzed for each patient. The analysis of laboratory values obtained at initial presentation, was similarly performed. Multiple laboratory values for the same patient were not analyzed. No correction was made for multiple comparison testing.

Peak (vs nadir) laboratory values and laboratory values on initial presentation were dichotomized on the basis of whether or not they fell within the normal clinical range as defined by our laboratory’s standard reference ranges. The prevalence of an abnormal laboratory finding was compared between pregnant patients who were symptomatic vs asymptomatic and symptomatic pregnant patients with mild to moderate disease vs those with severe to critical disease. Chi-square test and the Fisher exact test determined biomarker abnormalities significantly associated with symptomatic infection and disease severity. Peak (vs nadir) laboratory values and laboratory values on initial presentation that were significantly associated with symptomatic SARS-CoV-2 or severity of symptoms were evaluated with multivariable logistic regression. These multivariable regressions controlled for significant covariates to identify whether the identified laboratory abnormalities were independently associated with either symptoms or a more severe illness.

The remainder of our analysis involved analysis of only peak (vs nadir) laboratory values. The sensitivity and specificity of each laboratory abnormality identified in multivariable regression to be a significant predictor of clinical phenotype (ie, symptomatic vs asymptomatic infection; mild to moderate disease vs severe to critical disease) were calculated. Moreover, sensitivity analysis, excluding pregnant patients treated with dexamethasone, which is known to contribute to leukocytosis, was performed for neutrophilia, lymphopenia, and leukopenia among pregnant patients with symptomatic SARS-CoV-2 infection according to disease severity. Of note, at our institution, any patient with a positive SARS-CoV-2 test result warranting antenatal corticosteroid administration for fetal benefit received dexamethasone, not betamethasone. Additional sensitivity analyses among symptomatic patients excluded patients who had laboratory assessments during labor or within 48 hours after delivery, as biomarker levels can be altered by physiological changes during labor and immediately after delivery.

Statistical analyses were conducted using Stata (version 16.1.844; StataCorp LLC, College Station, TX). The study was approved by the Northwestern University Feinberg School of Medicine Institutional Review Board (IRB number, STU00212232) before its initiation and obtained a waiver of written consent.

Results

During the study period, 175 pregnant patients were identified to have a positive PCR test confirming SARS-CoV-2 infection, of whom 100 (57%) were symptomatic (Figure 1). Only 1 asymptomatic patient was tested solely because of exposure to a known positive case contact; all other asymptomatic patients were tested per universal screening protocol. The median gestational age at diagnosis was 39 weeks in symptomatic patients and 29.6 weeks in asymptomatic patients (P<.001), with 43% of patients with a symptomatic disease identified before the third trimester of pregnancy (Table 1). Of note, 46% and 23% of symptomatic and asymptomatic patients, respectively, reported known exposure to a positive case contact (P=.003). There was no statistically significant difference in parity, race, ethnicity, or maternal comorbidities between those who were symptomatic and those who were asymptomatic. Among symptomatic individuals, pregnant patients with severe to critical disease were older (P=.03) and more likely to be obese (P=.004) than those with mild to moderate disease; baseline characteristics were similar between those with mild to moderate disease and those with severe to critical disease. The most common medical comorbidities reported by disease severity are described in Table 1.

Among symptomatic pregnant patients, 60% had mild disease, 23% had moderate disease, 16% had severe disease, and 1% (1 person) had a critical disease. The commonly reported symptoms were cough (63%), fever (41%), and shortness of breath (40%) (Figure 2). Moreover, 30 symptomatic
pregnant individuals (30%) were hospitalized for supportive care and further management of SARS-CoV-2 infection, 13 (43%) of whom had mild to moderate disease and the remaining 17 (57%) with severe to critical disease. Most asymptomatic women (94.6%) were identified during a hospitalization for delivery, whereas only 26.5% of symptomatic women were identified during a hospitalization for delivery.

Laboratory data were available for 128 patients, of whom 61 (48%) were asymptomatic and 67 (52%) were symptomatic. When peak (vs nadir) laboratory markers as continuous variables were compared between symptomatic and asymptomatic pregnant patients, those with symptomatic infection had decreased leukocyte nadir and increased peak neutrophil percentage, ferritin, ALT, AST, hsCRP, PCT, and LDH (Table 2). A similar analysis for laboratory values obtained at initial presentation, has been demonstrated in Supplemental Table 1.

Laboratory markers were dichotomized as normal vs abnormal. For peak (vs nadir) laboratory values and those obtained at initial presentation, only leukocytosis (compared with the absence of leukocytosis, with leukocytosis defined as white blood cell count of >10.5 K/μL), leukopenia (compared with the absence of leukopenia, with leukopenia defined as white blood cell count of <4 K/μL), and an elevated hsCRP level (compared with a normal hsCRP level, defined as <10 mg/L) were significantly associated with symptomatic infection (Table 3; Supplemental Table 2). Neutrophil percentage, lymphocyte percentage, transaminitis, and elevations in ferritin, D-dimer, LDH, and PCT levels were not associated with a symptomatic disease. After adjusting the peak value for gestational age at diagnosis, pregnant patients with an elevated hsCRP level had more than a 4-fold odds of having a symptomatic disease. Within the subgroup of pregnant patients who had symptoms, lymphopenia (compared with the absence of lymphopenia, with lymphopenia defined as lymphocyte percentage of <20%), transaminitis (compared with normal liver transaminases, with elevated ALT defined as >52 units/L and elevated AST defined as >39 units/L), an elevated PCT level (compared with normal PCT level, defined as <0.065 ng/mL), and an elevated LDH level (compared with normal LDH level, defined as <271 units/L) were associated with severe to critical disease (Table 4) in analysis by peak (vs nadir) laboratory values. Neutrophil percentage, leukocyte count, and elevated ferritin, D-dimer, and hsCRP levels were not
associated with disease severity among pregnant patients with symptomatic SARS-CoV-2 infection. After adjusting for age and obesity in analysis by peak (vs nadir) laboratory values, transaminitis, an elevated PCT level, and an elevated LDH level were each associated with having a severe to critical disease.

In the analysis of laboratory values obtained at initial presentation, an elevated PCT level was no longer significant (Supplemental Table 3).

Regarding test characteristics for peak laboratory values, hsCRP showed moderate sensitivity (81%) but poor specificity (43%) for distinguishing symptomatic vs asymptomatic infection. Moreover, the sensitivity and specificity for each of these biomarkers to differentiate disease severity among symptomatic patients were suboptimal, with a sensitivity of 47%, 87%, and 53% for transaminitis, PCT elevation, and LDH elevation, respectively, and a specificity of 89%, 63%, and 90%, respectively (Table 5).

In a planned sensitivity analysis of peak (vs nadir) laboratory values, excluding 3 individuals treated with dexamethasone, neutrophilia (odds ratio [OR], 5.11; 95% confidence interval [CI], 0.59–43.85), lymphopenia (OR, 7.28; 95% CI, 0.86–61.67), and

| Variable                              | Asymptomatic (n=75) | Symptomatic (n=100) | P value | Mild to moderate (n=83) | Severe to critical (n=17) | P value |
|---------------------------------------|---------------------|---------------------|---------|-------------------------|--------------------------|---------|
| Maternal age (y)                      | 29.30±6.06          | 30.20±6.20          | .39     | 29.50±5.90              | 33.20±6.90               | .03     |
| Gestational age at diagnosis          |                     |                     |         |                         |                          |         |
| By trimester                          |                     |                     |         |                         |                          |         |
| First trimester                       | 39.0 (16.3–41.1)    | 29.6 (3.6–41.0)    | <.001   | 31.1 (16.0–36.4)        | .81                      |         |
| Second trimester                      | 0 (0)               | 5 (5.0)             | <.001   | 5 (6.0)                 | 0 (0)                    | .83     |
| Third trimester                       | 1 (1.4)             | 38 (38.0)           |         | 31 (37.0)               | 7 (41.0)                 |         |
| Nulliparous                           | 74 (99.0)           | 57 (57.0)           |         | 47 (57.0)               | 10 (59.0)                |         |
| Self-reported race                    |                     |                     |         |                         |                          |         |
| Black                                 | 21 (28.0)           | 23 (23.0)           | .74     | 18 (22.0)               | 5 (29.0)                 | .85     |
| White                                 | 19 (26.0)           | 30 (30.0)           |         | 25 (30.0)               | 5 (29.0)                 |         |
| Asian                                 | 2 (3.0)             | 5 (5.0)             |         | 5 (6.0)                 | 0 (0)                    |         |
| Other*                                | 32 (43.0)           | 42 (42.0)           |         | 35 (42.0)               | 34 (41.0)                |         |
| Hispanic ethnicity                    | 35 (47.0)           | 55 (55.0)           | .32     | 43 (52.0)               | 12 (71.0)                | .16     |
| Maternal comorbidities                |                     |                     |         |                         |                          |         |
| Asthma or pulmonary disease           | 10 (13.0)           | 21 (21.0)           | .18     | 16 (19.0)               | 5 (29.0)                 | .35     |
| Obesity (body mass index ≥30 kg/m²)   | 40 (53.0)           | 57 (57.0)           | .63     | 42 (51.0)               | 15 (88.0)                | .004    |
| Chronic hypertension                  | 4 (5.0)             | 12 (12.0)           | .19     | 9 (11.0)                | 3 (18.0)                 | .42     |
| Immunosuppressive disease or medication| 4 (5.0)             | 3 (3.0)             | .46     | 2 (2.0)                 | 1 (6.0)                  | .43     |
| Pregestational diabetes mellitus      | 3 (4.0)             | 6 (6.0)             | .73     | 5 (6.0)                 | 1 (6.0)                  | .99     |
| Gestational diabetes mellitus         | 8 (11.0)            | 14 (14.0)           | .46     | 9 (13.0)                | 5 (29.0)                 | .05     |

Data are presented as mean±standard deviation, median (interquartile range), or number (percentage), unless otherwise indicated.

* The standard reported race categories within our electronic medical record system include White, Black, Asian, American Indian or Alaskan Native, Native Hawaiian or Other Pacific Islander, or "other." We have condensed American Indian or Alaskan Native and Native Hawaiian or Other Pacific Islander into "other." Several patients of Hispanic ethnicity selected "other" as their identified race.

Fisher. Laboratory analysis of SARS-CoV-2 in pregnant patients. Am J Obstet Gynecol MFM 2021.
TABLE 2
Peak (vs nadir) laboratory characteristics in pregnant patients stratified by the presence or absence of symptoms and disease severity

| Variable          | n     | Asymptomatic | N | Symptomatic | Pvalue | n     | Mild to moderate | n | Severe to critical | Pvalue |
|-------------------|-------|--------------|---|-------------|--------|-------|------------------|---|-------------------|--------|
| Neutrophils (%)   |       |              |   |             |        |       |                  |   |                   |        |
| Highest           | 42    | 75.5 (58–90) | 56 | 77.0 (44–94) | .29    | 39    | 75.0 (44–93)    | 17 | 82.0 (72–94)      | <.001  |
| Lowest            | 42    | 72.0 (0–90)  | 56 | 67.5 (42–86) | .02    | 39    | 70.0 (42–80)    | 17 | 66.0 (61–86)      | .39    |
| Lymphocytes (%)   |       |              |   |             |        |       |                  |   |                   |        |
| Highest           | 42    | 18.0 (6–45)  | 56 | 21.0 (7–49)  | .09    | 39    | 20.0 (7–49)     | 17 | 24.0 (12–30)      | .70    |
| Lowest            | 42    | 18.0 (5–34)  | 56 | 16.0 (0–33)  | .21    | 39    | 17.0 (3–33)     | 17 | 11.0 (0–18)       | <.001  |
| Leukocytes (%)    |       |              |   |             |        |       |                  |   |                   |        |
| Highest           | 61    | 10.8 (5.7–24.4) | 67 | 8.8 (3.1–64.4) | <.001  | 44    | 8.3 (3.1–14.9)  | 17 | 10.4 (4.2–64.4)   | .26    |
| Lowest            | 61    | 9.3 (7.7–11.4) | 67 | 6.1 (4.8–8.3)  | <.001  | 44    | 6.9 (2.9–16.1)  | 17 | 5.1 (3.5–8.3)     | .004   |
| Ferritin          |       |              |   |             |        |       |                  |   |                   |        |
| Highest           | 27    | 16.5 (6.2–817.6)| 40 | 44.3 (8.5–15,695.4)| .001  | 26    | 23.8 (8.5–175.6)| 14 | 81.8 (17.9–15,695.4)| .003  |
| Lowest            | 27    | 15.8 (5.9–22.5)| 40 | 10.0 (0.2–91.5) | .005  | 27    | 12.9 (0.9–219.5)| 15 | 76.2 (36.4–203.6) | <.001  |
| ALT               |       |              |   |             |        |       |                  |   |                   |        |
| Highest           | 37    | 774 (242–6907)| 47 | 613 (187–17,106) | .03   | 31    | 564 (187–3411)  | 16 | 689 (262–17,106)  | .50    |
| Lowest            | 37    | 267 (212–1,000)| 47 | 112 (38–12,000) | .02   | 32    | 215 (60–8,000)  | 15 | 195 (0.0–19.0)    | <.001  |
| LDH               |       |              |   |             |        |       |                  |   |                   |        |
| Highest           | 47    | 224 (123–521)| 47 | 221 (112–12,000)| .60   | 30    | 193 (112–10,851)| 17 | 267 (151–12,000)  | <.001  |

Data are presented as median (interquartile range), unless otherwise indicated. Reference range: neutrophils (55%–70%), lymphocytes (20%–40%), leukocytes (4.0–10.5 K/µL), ferritin (11–307 ng/mL), ALT (0–52 unit/L), AST (0–39 unit/L), hsCRP (0–10 mg/L), D-dimer (0–230 D-DU ng/mL), PCT (0.000–0.065 ng/mL), and LDH (0–271 unit/L).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; hsCRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase; PCT, procalcitonin.

Fisher. Laboratory analysis of SARS-CoV-2 in pregnant patients. Am J Obstet Gynecol MFM 2021.

TABLE 3
Peak (vs nadir) laboratory abnormalities identified among pregnant patients with SARS-CoV-2 infection stratified by the presence or absence of symptoms

| Variable                  | n     | Asymptomatic | N | Symptomatic | Pvalue | OR (95% CI) | Adjusted OR (95% CI) |
|---------------------------|-------|--------------|---|-------------|--------|-------------|----------------------|
| Neutrophilia              | 42    | 28 (66.7)    | 56 | 45 (80.4)   | .12    | 2.05 (0.82–5.13) | —                    |
| Neutropenia               | 42    | 1 (2.4)      | 56 | 3 (5.4)     | .42    | 2.32 (0.23–23.14) | —                    |
| Lymphocytosis             | 42    | 1 (2.4)      | 56 | 2 (3.6)     | .62    | 1.48 (0.13–16.91) | —                    |
| Lymphopenia               | 42    | 27 (64.3)    | 56 | 42 (75.0)   | .25    | 1.67 (0.70–3.99)  | —                    |
| Leukocytosis              | 61    | 34 (67.1)    | 67 | 18 (26.9)   | .02    | 0.41 (0.20–0.84)  | 0.48 (0.19–1.18)     |
| Leukopenia                | 61    | 0 (0)        | 67 | 7 (10.4)    | .01    | 8.42 (1.01–70.6)  | 4.97 (0.37–66.65)    |
| Elevated ferritin level   | 27    | 1 (3.7)      | 40 | 2 (5.0)     | .62    | 1.37 (0.12–15.89) | —                    |
| Transaminis               | 50    | 6 (11.8)     | 53 | 12 (21.8)   | .16    | 2.15 (0.74–6.25)  | —                    |
| Elevated hsCRP level      | 30    | 17 (56.7)    | 42 | 34 (81.0)   | .03    | 3.25 (1.13–9.34)  | 4.51 (1.11–18.40)    |
| Elevated D-dimer level    | 37    | 37 (100.0)   | 47 | 45 (95.7)   | .20    | 0.63 (0.05–7.17)  | —                    |
| Elevated PCT level        | 38    | 17 (44.7)    | 47 | 25 (53.2)   | .44    | 1.40 (0.59–3.31)  | —                    |
| Elevated LDH level        | 47    | 10 (21.3)    | 47 | 12 (25.5)   | .63    | 1.27 (0.49–3.31)  | —                    |

Data are presented as number (percentage), unless otherwise indicated.

Adjusted ORs are adjusted for gestational age.

CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase; OR, odds ratio; PCT, procalcitonin.

Fisher. Laboratory analysis of SARS-CoV-2 in pregnant patients. Am J Obstet Gynecol MFM 2021.
leukopenia (OR, 2.73; 95% CI, 0.53–14.04) were not significant in bivariable analysis of biomarkers according to disease severity in pregnant patients with symptomatic SARS-CoV-2 infection. In additional sensitivity analysis among symptomatic patients, excluding those who had laboratory assessment done during labor or after delivery, only elevated PCT levels (adjusted OR, 10.85; 95% CI, 1.44–81.88) and elevated LDH levels (adjusted OR, 8.90; 95% CI, 1.06–75.10) were significantly associated with severe to critical disease; transaminitis was no longer significantly associated with disease severity (OR, 3.0; 95% CI, 0.57–15.87).

**Comment**

**Principal findings**

In our cohort of 175 pregnant patients with SARS-CoV-2 infection, we identified a relatively low but clinically important subset of patients with severe and critical diseases (17%). Among our analytical cohort of 128 patients with data on inflammatory biomarkers available, we observed a vast heterogeneity in measured biomarker levels among pregnant patients with SARS-CoV-2 infection even within cohorts (eg, among those who were asymptomatic or among those with mild to moderate disease). This pronounced heterogeneity decreases the discriminatory strength of any 1 specific inflammatory marker to differentiate the clinical phenotypes of the disease. Of all inflammatory markers analyzed, only hsCRP was independently associated with a symptomatic disease. However, 55% of patients with an asymptomatic disease had an abnormally elevated hsCRP level, making the specificity of this biomarker as a discriminatory test clinically not useful.

Among symptomatic pregnant patients, elevated liver enzymes and elevated PCT and LDH levels for peak laboratory values were all significantly associated with a severe or critical disease. Transaminitis and LDH both demonstrated poor performance as a

### TABLE 4

**Peak (vs nadir) laboratory abnormalities identified among pregnant patients with symptomatic SARS-CoV-2 infection stratified by disease severity**

| Variable                  | n     | Mild to moderate | Severe to critical | P value | OR (95% CI)       | Adjusted OR (95% CI) |
|---------------------------|-------|------------------|--------------------|---------|------------------|----------------------|
| Neutrophilia              | 39    | 28 (71.8)        | 17                 | .06     | 6.29 (0.74–53.28) | —                    |
| Lymphopenia               | 39    | 3 (7.7)          | 17                 | .33     | 0.75 (0.07–7.77)  | —                    |
| Lymphocytosis             | 39    | 2 (5.1)          | 17                 | .48     | 1.16 (0.10–13.68) | —                    |
| Lymphopenia               | 39    | 25 (64.1)        | 17                 | .003    | 8.96 (1.07–74.91) | 7.08 (0.80–62.62)    |
| Leukocytosis              | 44    | 11 (25.0)        | 17                 | .21     | 2.10 (0.64–6.85)  | —                    |
| Lymphopenia               | 44    | 4 (9.1)          | 17                 | .30     | 2.14 (0.43–10.78) | —                    |
| Elevated ferritin level   | 26    | 0 (0)            | 14                 | .12     | 4.17 (0.34–50.61) | —                    |
| Transaminitis             | 36    | 4 (11.1)         | 17                 | .006    | 7.11 (1.74–29.1)  | 5.67 (1.27–25.43)    |
| Elevated hsCRP level      | 27    | 19 (70.4)        | 15                 | .09     | 5.89 (0.66–52.70) | —                    |
| Elevated D-dimer level    | 31    | 29 (93.6)        | 16                 | .43     | 1.03 (0.09–12.35) | —                    |
| Elevated PCT level        | 32    | 12 (62.5)        | 15                 | .002    | 10.83 (2.08–56.51)| 16.60 (2.61–105.46) |
| Elevated LDH level        | 30    | 3 (10.0)         | 17                 | .002    | 10.13 (2.20–46.59)| 17.55 (2.51–122.78) |

Data are presented as number (percentage), unless otherwise indicated.

Adjusted ORs are adjusted for maternal age and obesity.

CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase; OR, odds ratio; PCT, procalcitonin.

*Fisher. Laboratory analysis of SARS-CoV-2 in pregnant patients. Am J Obstet Gynecol MFM 2021.*

### TABLE 5

**Test characteristics of identified peak laboratory abnormalities in pregnant patients associated with clinical phenotype**

| Asymptomatic vs symptomatic infection | Sensitivity (95% CI) | Specificity (95% CI) |
|--------------------------------------|----------------------|----------------------|
| Elevated hsCRP level                 | 81.0 (65.9–91.4)     | 43.3 (25.5–62.6)     |

| Mild to moderate disease vs severe to critical disease | Sensitivity (95% CI) | Specificity (95% CI) |
|------------------------------------------------------|----------------------|----------------------|
| Transaminitis                                        | 47.1 (23.0–72.2)     | 88.9 (73.9–96.9)     |
| Elevated PCT level                                   | 86.7 (59.5–98.3)     | 62.5 (43.7–78.9)     |
| Elevated LDH level                                   | 52.9 (27.8–77.0)     | 90.0 (73.5–97.9)     |

CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase; PCT, procalcitonin.

Sensitivity and specificity are reported in percentages (%).

*Fisher. Laboratory analysis of SARS-CoV-2 in pregnant patients. Am J Obstet Gynecol MFM 2021.*
screening test with high false-negative rates but demonstrated greater diagnostic ability for distinguishing severe to critical disease from mild to moderate disease with specificity approaching 89% to 90%. Elevated peak PCT demonstrated improved performance as a screening test but demonstrated poor performance as a diagnostic test for a more severe disease as reflected by the test sensitivity and specificity. Overall, the discriminatory ability of these laboratory tests to distinguish disease severity in symptomatic pregnant patients was poor and suggested that they have limited use in clinical practice.

Results

Although the obstetrical literature on inflammatory biomarkers associated with SARS-CoV-2 infection has demonstrated mixed results, several studies evaluating nonpregnant individuals with SARS-CoV-2 infection have noted that elevated D-dimer levels, neutrophil counts, ferritin levels, liver enzymes, LDH levels, and CRP levels and decreased lymphocyte counts have utility in differentiating morbidity and mortality risks resulting from widespread systemic inflammation. However, we must consider that normal reference ranges for laboratory results may be altered by physiological changes in pregnancy. Normal reference ranges for hsCRP and PCT have not been identified for pregnancy, although PCT is basally expressed at very low levels in pregnancy, whereas median CRP values in normal pregnancies seem to be higher than standardized values for nonpregnant individuals. Pregnancy itself does not affect LDH levels or liver enzymes, although these can be elevated in the setting of preeclampsia or other liver diseases associated with pregnancy. Moreover, leukocytosis, primarily related to increased circulation of neutrophils, without significant alteration in lymphocyte count is associated with the normal pregnancy state. Finally, although elevated ferritin levels can be an indicator of infection in pregnancy, ferritin levels can be reduced as a result of hemodilution that is characteristic of pregnancy. Therefore, it is possible that certain biomarker levels in our cohort may be labeled “normal” or “abnormal” merely because of pregnancy physiology and not solely because of SARS-CoV-2 infection. We must interpret the trends in laboratory markers identified and their clinical significance with caution in our pregnant cohort given baseline alterations because of normal pregnancy physiology.

The previous evaluation of inflammatory biomarkers in pregnant patients with SARS-CoV-2 infection according to symptomatology and disease severity was limited and demonstrated mixed results (Table 6).

### TABLE 6

| Study author, year, year | Number of subjects | Nonpregnant vs pregnant patients | Neutrophils | Lymphocytes | Leukocytes | D-dimer | ALT | AST | CRP | PCT | LDH |
|-------------------------|--------------------|---------------------------------|-------------|-------------|------------|---------|-----|-----|-----|-----|-----|
| Liu et al, 2020         | 14/16              |                                 | ↑           | X           | ↑          |         |     |     |     |     |     |
| Wang et al, 2020        | 42/30              |                                 | ↑           | X           | ↑          | ↑       | X   | X   | ↑   | ↑   | X   |

| Asymptomatic vs symptomatic pregnant patients |
|-----------------------------------------------|
| Grechukhina et al, 2020 | 12/7 | X | X | |
| Fisher et al, 2021 (current study) | 61/67 | X | X | X | |

| Pregnant patients stratified by severe vs critical disease |
|----------------------------------------------------------|
| Pierce-Williams et al, 2020 | 44/20 | X | X | X | |

| Pregnant patients stratified by mild to moderate disease vs severe disease |
|----------------------------------------------------------------------------|
| Pereira et al, 2020 | 10/2 | ↑ | X | ↑ | X | X | ↑ | |
| Fisher et al, 2021 (current study) | 39/17 | X | X | X | X | X | X | |

The “X” indicates no significant difference identified between the groups, and the symbol “↑” indicates a significant increase in the laboratory values identified.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; LDH, lactate dehydrogenase; PCT, procalcitonin.

Fisher. Laboratory analysis of SARS-CoV-2 in pregnant patients. Am J Obstet Gynecol MFM 2021.
Moreover, 2 studies compared the biomarkers between pregnant women and nonpregnant women with SARS-CoV-2 infection, although the studies did not include subgroups for symptomatic disease or disease severity.17,18 Shi et al19 published a meta-analysis of 173 people in 11 studies, evaluating biomarkers among pregnant women dichotomized as elevated vs normal and did not find elevated CRP or LDH levels to be associated with SARS-CoV-2 infection in pregnant women, although there was no attention to symptomatic disease or disease severity. Grechukhina et al20 evaluated CRP and D-dimer levels in 19 asymptomatic and symptomatic pregnant women, with no significant difference identified between the groups. In contrast, we identified abnormally elevated hsCRP levels to be independently associated with a symptomatic disease.

Notably, 2 studies have evaluated biomarker abnormalities in pregnant women according to disease severity, the largest with 64 individuals; both studies identified elevated CRP levels to be associated with greater disease severity, but neither study identified a significant association between liver enzymes and disease severity.25,26 Although we did not identify hsCRP to be independently associated with a more severe disease in pregnant patients, we identified liver enzymes to be significantly associated with disease severity. Furthermore, Pierce-Williams et al25 identified elevated PCT and LDH levels to be associated with greater disease severity, whereas Pereira et al26 did not find LDH to be associated with disease severity. Similar to Pierce-Williams et al,25 we identified elevated PCT and LDH levels for peak laboratory values to be independently associated with a more severe disease. Previous studies have not evaluated test characteristics, such as the sensitivity and specificity of these biomarkers for risk stratification and prognostication among pregnant individuals with SARS-CoV-2 infection; the poor discriminatory ability of these tests as we have identified among our cohort may account for the variable differences in significant laboratory markers identified in those studies.

**Clinical and research implications**

Although the inflammatory biomarkers evaluated in our cohort of pregnant patients did not seem to be clinically useful for discriminating between symptomatic and asymptomatic infection or particularly indicative of disease severity, other clinical applications of these biomarkers remain unclear. Previous studies have commented on the use of elevated D-dimer levels to guide prophylactic anticoagulation in patients with a more severe SARS-COV-2 infection either during inpatient admission or following delivery.25,26 In addition, elevated PCT has been demonstrated to be a marker for increased risk of bacterial infection in patients with SARS-CoV-2 infection, and more specifically superimposed bacterial pneumonia, that may support antibiotic therapy.20 However, evaluation of the ability of these inflammatory biomarkers to predict coagulopathy or bacterial superinfection and guide treatment in pregnant patients was beyond the scope of this manuscript. Future studies should further evaluate the clinical applications of inflammatory biomarkers in pregnant patients with SARS-CoV-2 infection, considering pregnancy physiology.

**Strengths and limitations**

Our study was strengthened by the diverse patient population and comprehensive array of inflammatory biomarkers evaluated. Our results were likely generalizable to other pregnant individuals in the United States. In addition, our large cohort afforded us the ability to control for potential confounders, notably gestational age at diagnosis, maternal age, and presence of obesity. Each of these factors could influence the laboratory values assessed.

To our knowledge, although this cohort is the largest cohort to analyze laboratory markers of disease in pregnant individuals with clinically phenotyped SARS-CoV-2 infection, the small sample size and missing data, particularly within smaller subgroups and among asymptomatic patients, may lead to type II error. Missing data, specifically as it is not missing at random, further introduce additional selection bias, limiting our ability to firmly conclude the frequency of abnormal laboratory results and the validity of comparisons between the groups. Moreover, changes in criteria for testing throughout the pandemic limited our ability to determine the proportion of pregnant individuals tested who will have a symptomatic infection. Changes in the care and management of patients with SARS-CoV-2 infection occurred throughout the study period with different treatments having the potential to affect peak biomarker levels; however, our study conclusions were less likely to be impacted by the evolving treatment methods given the relative consistency in findings in our analysis of laboratory values obtained on initial presentation with that of peak laboratory values.

It is important to note that this was an epidemiologic, cross-sectional analysis evaluating peak laboratory values, or nadir in the case of leukocyte count and differential, based on available laboratory data captured among pregnant patients in the hospital setting as a proxy for the most severe point in the clinical course of patients’ disease. We could not comment on biomarker trends over time throughout a patient’s disease, and we could not fully capture laboratory data for pregnant patients managed primarily in the outpatient setting. Particularly in asymptomatic patients identified on admission and among symptomatic individuals, the actual timing of infection was unknown, and it was plausible that peak biomarker levels could have occurred before, or even after, admission.

**Conclusions**

Inflammatory biomarkers used to differentiate morbidity in nonpregnant patients with SARS-CoV-2 infection demonstrated poor diagnostic ability and thereby limited clinical utility in pregnant patients. Given the severity of infection in pregnant individuals, ongoing large registry studies are needed to further evaluate which inflammatory biomarkers may be most useful for risk stratification and prognostication of pregnant patients with SARS-CoV-2...
infection, considering the pregnancy physiology.

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajogmf.2021.100458.

References
1. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep 2020;69:769–75.
2. Panagiotakopoulos L, Myers TR, Gee J, et al. Coronavirus disease 2019 (COVID-19) infection. Obstet Gynecol 2020;136:291–9.
3. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395:809–15.
4. Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 2010;63:425–33.
5. Delahoy MJ, Whitaker M, O’Halloran A, et al. Characteristics and maternal and birth outcomes of hospitalized pregnant women with COVID-19 and severe COVID-19 in the United States from March 8 to July 11, 2020. Obstet Gynecol 2020;146:345–54.
6. Centers for Disease Control and Prevention. Data on COVID-19 during pregnancy: severity of maternal illness. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updated/special-populations/pregnancy-data-on-covid-19.html. Accessed Oct. 31, 2020.
7. Andrikopoulos L, Madden N, Wen T, et al. Symptoms and critical illness among obstetric patients with coronavirus disease 2019 (COVID-19) infection. Obstet Gynecol 2020;136:291–9.
8. Breslin N, Baptiste C, Gyaamfi-Bannerman C, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM 2020;2:100118.
9. Li N, Han L, Peng M, et al. Maternal and neonatal outcomes of pregnant women with coronavirus disease 2019 (COVID-19) pneumonia: a case-control study. Clin Infect Dis 2020;71:2035–41.
10. Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. J Med Virol 2020;92:1556–61.
11. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 - a systematic review. Life Sci 2020;254:117788.
12. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med 2021;26:107–8.
13. Danwang C, Endomba FT, Kneck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res 2020;8:37.
14. Ponti G, Maccarferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020;57:389–99.
15. Aboughdr M, Kirwin T, Abdul Khader A, Wang B. Prognostic value of cardiovascular biomarkers in COVID-19: a review. Viruses 2020;12:527.
16. Vlachodimitropoulou Koumoutsea EV, Vivanti AJ, Shehata N, et al. COVID-19 and acute coagulopathy in pregnancy. J Thromb Haemost 2020;18:1648–52.
17. Wang Z, Wang Z, Xiong G. Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan, China. Int J Gynaecol Obstet 2020;150:312–7.
18. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children. J Infect 2020;80:s7–13.
19. Chen L, Li Q, Zheng D, et al. Clinical characteristics of pregnant women with COVID-19 in Wuhan, China. N Engl J Med 2020;382:e100.
20. Shi L, Wang Y, Yang H, Duan G, Wang Y. Laboratory abnormalities in pregnant women with novel coronavirus disease 2019. Am J Perinatol 2020;37:1070–3.
21. Grechukhina O, Greenberg V, Lundsberg LS, et al. Coronavirus disease 2019 pregnancy outcomes in a racially and ethnically diverse population. Am J Obstet Gynecol MFM 2020:2:100246.
22. National Institutes of Health. COVID-19 Treatment Guidelines. Clinical spectrum of SARS-CoV-2 infection. 2021. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-presentation. Accessed Oct. 31, 2020.
23. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382:2372–4.
24. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009;114:1326–31.
25. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM 2020;2:100134.
26. Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy. Acta Obstet Gynecol Scand 2020;99:839–47.
27. Henry BM, de Oliveira MHS, Benoît S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8.
28. Watts DH, Krohn MA, Wener MH, Eschenbach DA. C-reactive protein in normal pregnancy. Obstet Gynecol 1991;77:176–80.
29. Mangogna A, Agostinis C, Rici G, Romano F, Bulla R. Overview of procalcitonin in pregnancy and pre-eclampsia. Clin Exp Immunol 2019;198:37–46.
30. Vazquez-Alaniz FS, Salas-Pacheco JM, Sandoval-Carrillo AA, et al. Lactate dehydrogenase in hypertensive disorders in pregnancy: severity or diagnosis marker? J Hypertens Manag 2019;5:040.
31. Hak J, Nisa NU, Gupta S. LDL levels in pregnancy and its association with severity of the disease and feto-maternal outcome in pre-eclampsia and eclampsia. JKI Sci 2020;12:527.
32. Nikolasevic I, Filipic-Kanizaj T, Jakopic I, et al. Liver disease during pregnancy: a challenging clinical issue. Med Sci Monit 2018;24:4080–90.
33. Kuvin SF, Brecher G. Differential neutrophil counts in pregnancy. N Engl J Med 1962;266:877–8.
34. Kühnert M, Strohmeier R, Stegmüller M, Halberstadt E. Changes in lymphocyte subsets during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 1998;76:147–51.
35. Scholl TO, Reilly T. Anemia, iron and pregnancy outcome. J Nutr 2000;130.443S–7S.
36. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–9.
37. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.
38. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
39. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.

40. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents* 2020;56:106051.

**Author and article information**

From the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL (Drs Fisher and Miller); Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL (Drs Goldstein and Shanes); Division of Infectious Diseases, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, IL (Dr Mithal and Mr Otero); Feinberg School of Medicine, Northwestern University, Chicago, IL (Ms Isaia).

The authors report no conflict of interest.

This project was supported by the Friends of Prentice Research Award (FY20-21). The funding source had no role in the study design; collection, analysis, and interpretation of data; or manuscript preparation.

Permission was obtained from the Northwestern University Feinberg School of Medicine Institutional Review Board (IRB number, STU00212232) for publication of this study.

All authors consent to the publication of these data. All authors gave final approval of the version to be published and are responsible for the accuracy and integrity of this work.

This work was presented at the 41st annual meeting of the Society for Maternal-Fetal Medicine, held virtually, January 25–30, 2021.

Corresponding author: Stephanie A. Fisher, MD, MPH. stephanie.fisher@northwestern.edu